Biosafety risk assessment and risk control of clinical laboratory in designated hospitals for treating COVID-19 in Chongqing, China

BACKGROUND: If a nucleic acid preservation solution containing viral inactivators is used, the biosafety risk in the process of detecting the nucleic acid of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will be low. Patients infected with SARS-CoV-2 are sent to designated hospitals f...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Yongpei, Chang, Fan, Yang, Fangyu, Hou, Yongbin, Mo, Zhan, Diao, Qizhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167147/
https://www.ncbi.nlm.nih.gov/pubmed/35671845
http://dx.doi.org/10.1016/j.ajic.2022.05.028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167147/
https://www.ncbi.nlm.nih.gov/pubmed/35671845
http://dx.doi.org/10.1016/j.ajic.2022.05.028

Ejemplares similares